Shilpa Medicare Limited has announced its financial results for FY26, reporting a significant 18% year-on-year growth in consolidated revenue to ₹1,549 crore from ₹1,310 crore in FY25. The company also achieved an all-time high EBITDA of ₹445 crore, marking a 30% increase year-on-year. Profit after tax saw a substantial jump of 211% to ₹243 crore, reflecting a strong performance across its API, Formulations, and Biologics segments.
Shilpa Medicare Reports Record Financial Performance for FY26
Shilpa Medicare Limited has posted its strongest year on record for FY26, with consolidated revenue rising 18% year-on-year to ₹1,549 crore from ₹1,310 crore in FY25. This robust growth was driven by a favourable product mix and improved utilization of capacities across its key business verticals.
Key Financial Highlights:
- Total Income: ₹1,549 crore (up 18% YoY)
- EBITDA: ₹445 crore (up 30% YoY), with an improved EBITDA margin of 29%.
- Profit Before Tax (PBT): ₹295 crore (up 142% YoY)
- Profit After Tax (PAT): ₹243 crore (up 211% YoY)
Profitability demonstrated a faster pace of growth than revenue, with gross profit increasing by 21% to ₹1,088 crore and gross margin expanding by 100 basis points to 70%. The API segment remained the largest contributor to revenue at 49% (₹769 crore), followed by Formulations at 40% (₹618 crore) and Biologics at approximately 10% (₹149 crore).
Segment Performance
The company reported significant growth across its business segments:
- API: Revenue grew 4% to ₹769 crore.
- Formulations: Delivered a standout performance, growing 30% year-on-year to ₹618 crore.
- Biologics: Saw remarkable growth of 99%, with revenue reaching ₹149 crore.
- Others: Revenue decreased by 48% to ₹13 crore.
The company’s strategic investments in R&D, manufacturing infrastructure, and regulatory capabilities have translated into measurable commercial outcomes, reinforcing its position as a trusted partner in the global pharmaceutical industry.
Source: BSE
